FINNENCE ▪ THE WIRE FILE
THE WIRE · № 72862
News■ Unclear/unknown
TRex Bio prices $117M IPO to support immune drug work
KINDNews
DIRECTION■ Unclear/unknown
SOURCES4
ENTITIES2
STORY SIZE4 RECORDS
FIRST SEEN2026-10-09 11:22 UTC
LAST UPDATE2026-10-09 12:33 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
A priced biotech IPO signals reopening issuance window for immune-drug developers.
Biotech IPO window shows selective reopening
CATALYST TO WATCH
Aftermarket trading performance
MAIN RISK
Single deal may not signal broad demand
02 THE STORY SO FAR
THE RECORD, IN ORDER.
UPDATED 4 TIMES · FIRST 2026-10-09 11:22 UTC · LAST 2026-10-09 12:33 UTC2026-10-09 11:22 UTCNewsTRex Bio prices $117M IPO to support immune drug workCURRENT RECORD
2026-10-09 11:51 UTCNewsTRex prices IPO at bottom of range as Retension makes 'oversized' public debut
2026-10-09 11:54 UTCNewsTRex Bio raised $116.7 million in a U.S. IPO, pricing at the bottom of its range
2026-10-09 12:33 UTCNewsCity Therapeutics IPO: RNAi biotech seeks up to $185 million
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
AFFECTEDSPDR Biotech ETF · XBI
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
Leading Through a Changing Water Management Landscape2026-10-09 11:40 UTC
Leading Through a Changing Water Management Landscape2026-10-09 11:40 UTC
→CORRELATIONshares Healthcare, XBI
TRex prices IPO at bottom of range as Retension makes 'oversized' public debut2026-10-09 11:51 UTC
TRex prices IPO at bottom of range as Retension makes 'oversized' public debut2026-10-09 11:51 UTC
→CORRELATIONshares Healthcare, XBI
TRex Bio raised $116.7 million in a U.S. IPO, pricing at the bottom of its range2026-10-09 11:54 UTC
TRex Bio raised $116.7 million in a U.S. IPO, pricing at the bottom of its range2026-10-09 11:54 UTC
→CORRELATIONshares Healthcare
HealthWorX Offers Employers a Safer Path to Lower Healthcare Costs as IRS Scrutiny of 105(b) Schemes Grows2026-10-09 12:31 UTC
HealthWorX Offers Employers a Safer Path to Lower Healthcare Costs as IRS Scrutiny of 105(b) Schemes Grows2026-10-09 12:31 UTC
→CORRELATIONshares Healthcare
Iambic sets IPO terms, seeking $150 million to advance AI-designed cancer drugs2026-10-09 11:15 UTC
Iambic sets IPO terms, seeking $150 million to advance AI-designed cancer drugs2026-10-09 11:15 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2) — Viking Therapeutics, Inc.2026-10-09 12:00 UTC
New Phase 3 trial: Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2) — Viking Therapeutics, Inc.2026-10-09 12:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.